It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1164/rccm.201606-1227CI | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High risk of drug-resistant tuberculosis in IGRA-negative contacts: should preventive treatment be considered?
Infection
January 2025
Department of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Parkallee 35, Borstel, Germany.
Purpose: Deciding whether to provide preventive treatment to contacts of individuals with multidrug-resistant (MDR) tuberculosis is complex.
Methods: We present the diagnostic pathways, clinical course and outcome of tuberculosis treatment in eight siblings from a single family. Tuberculosis disease was diagnosed by Mycobacterium tuberculosis culture and molecular detection of M.
Association between Sputum Culture Conversion and Body Mass Index among Multidrug-Resistant Tuberculosis Patients in Punjab, Pakistan: A Multicenter Retrospective Study.
Curr Mol Med
January 2025
College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310012, China.
Background: The global challenge of Multidrug-resistant Tuberculosis (MDR-TB) presents a substantial public health concern, requiring extended and complex treatment regimens. Understanding the factors impacting treatment results, particularly sputum culture conversion and Body Mass Index (BMI), is crucial. This retrospective cohort investigation conducted in Punjab, Pakistan, sought to explore the correlation between BMI and sputum culture conversion in individuals diagnosed with MDR-TB.
View Article and Find Full Text PDFMultifunctional Mycobacterial Topoisomerases with Distinctive Features.
ACS Infect Dis
January 2025
Department of Microbiology and Cell Biology, Indian Institute of Science, C.V. Raman Avenue, Bangalore 560012, India.
Tuberculosis (TB) continues to be a major cause of death worldwide despite having an effective combinatorial therapeutic regimen and vaccine. Being one of the most successful human pathogens, retains the ability to adapt to diverse intracellular and extracellular environments encountered by it during infection, persistence, and transmission. Designing and developing new therapeutic strategies to counter the emergence of multidrug-resistant and extensively drug-resistant TB remains a major task.
View Article and Find Full Text PDFEvaluation of extracts from used Xpert MTB/RIF cartridges for detection of resistance to second-line anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis in Ethiopia.
BMC Microbiol
January 2025
Mycobacteriology Research Center, Institute of Health, Jimma University, Jimma, Oromia, Ethiopia.
Background: Early and accurate diagnosis of drug resistance, including resistance to second-line anti-tuberculosis (TB) drugs, is crucial for the effective control and management of pre-extensively drug-resistant TB (pre-XDR-TB) and extensively drug-resistant TB (XDR-TB). The Xpert MTB/XDR assay is the WHO recommended method for detecting resistance to isoniazid and second-line anti-TB drugs when rifampicin resistance is detected. Currently, the Xpert MTB/XDR assay is not yet implemented in Ethiopia, thus the MTBDRsl assay continues to be used.
View Article and Find Full Text PDFPolicy analysis: Key milestones in MDR-TB management over the past decade in South Africa.
J Public Health Afr
December 2024
School of Nursing, Faculty of Community and Health Sciences, University of the Western Cape, Cape Town, South Africa.
Background: Significant strides have been made globally and in South Africa (SA) in the policy and biomedical management of multidrug-resistant tuberculosis (MDR-TB). However, MDR-TB remains a significant public health threat.
Aim: This policy content analysis aims to explore the key milestones in MDR-TB management in SA and globally over the last decade, 2013-2023, to identify gaps and opportunities for improvement.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!